EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TLR7 activation by imiquimod worsens glycemic control in female FVB /N mice consuming a high‐fat diet

Rahul M Kakalij iD, Del L Dsouza iD, LiGyeom Ha iD, Erika I Boesen iD

Physiological Reports · 2024-02 · 12 (3)

DOI: 10.14814/phy2.15949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiological Reports, online erschienen am 12.02.2024. Verfasst von Rahul M Kakalij und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Metabolic Syndrome, Autoimmune Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll‐like receptor‐7 (TLR7) activation promotes autoimmunity, and metabolic syndrome (MetS) is a common comorbidity in patients with autoimmune disease. We previously demonstrated hyperinsulinemia in TLR7 agonist imiquimod (IMQ)‐treated, high‐fat diet (HFD)‐fed female C57BL/6 mice. Since mouse strains differ in susceptibility to MetS and target organ damage, this study investigated whether 12 weeks of exposure to HFD and IMQ promoted MetS, autoimmunity, and target organ damage in female FVB/N mice. Supporting early‐stage autoimmunity, spleen‐to‐tibia ratio, and anti‐nuclear antibodies (ANA) were significantly increased by IMQ. No significant effect of IMQ on urinary albumin excretion or left ventricular hypertrophy was observed. HFD increased liver‐to‐tibia ratio, which was further exacerbated by IMQ. HFD increased fasting blood glucose levels at the end of 12 weeks, but there was no significant effect of IMQ treatment on fasting blood glucose levels at 6 or 12 weeks of treatment. However, oral glucose tolerance testing at 12 weeks revealed impaired glucose tolerance in HFD‐fed mice compared to control diet mice together with IMQ treatment exacerbating the impairment. Accordingly, these data suggest TLR7 activation also exacerbates HFD‐induced dysregulation of glucose handling FVB/N mice, supporting the possibility that endogenous TLR7 activation may contribute to dysglycemia in patients with autoimmune disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeAutoimmune DiseasesHumansFemaleMiceAnimalsImiquimodDiet, High-FatBlood GlucoseToll-Like Receptor 7Glycemic ControlMice, Inbred C57BLMice, Inbred Strains

Stichwörter der Autor:innen

autoimmunityhyperglycemiaimiquimodmetabolic syndrometoll-like receptor 7

Substanzen

ImiquimodBlood GlucoseToll-Like Receptor 7TLR7 protein, human

Autor:innen und Institutionen

  • Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.

ORCID-Profile: Rahul M Kakalij, Del L Dsouza, LiGyeom Ha, Erika I Boesen

Zitieren

APA

Kakalij, R. M., Dsouza, D. L., Ha, L., & Boesen, E. I. (2024). TLR7 activation by imiquimod worsens glycemic control in female FVB /N mice consuming a high‐fat diet. Physiological Reports, 12(3). https://doi.org/10.14814/phy2.15949

Vancouver

Kakalij RM, Dsouza DL, Ha L, Boesen EI. TLR7 activation by imiquimod worsens glycemic control in female FVB /N mice consuming a high‐fat diet. Physiological Reports. 2024;12(3). doi:10.14814/phy2.15949

BibTeX
@article{Kakalij2024,
  author = {Kakalij, Rahul M and Dsouza, Del L and Ha, LiGyeom and Boesen, Erika I},
  title = {TLR7 activation by imiquimod worsens glycemic control in female FVB /N mice consuming a high‐fat diet},
  journal = {Physiological Reports},
  year = {2024},
  volume = {12},
  number = {3},
  doi = {10.14814/phy2.15949}
}
Kostenlos starten →